Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/cpt.1910 http://scihub22266oqcxt.onion/10.1002/cpt.1910 32438454!7280639!32438454     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Pharmacol+Ther 2020 ; 108 (4): 719-729 Nephropedia Template TP {{tp|p=32438454|t=2020. Management of Osteoarthritis During the COVID-19 Pandemic |pdf=|usr=}}{{32438454}} gab.com Text Management of Osteoarthritis During the COVID-19 Pandemic JO: Clin Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=32438454 #FOAvip The pandemic spread of the new coronavirus disease 2019 (COVID-19) infection in China first, and all over the world at present, has become a global health emergency due to the rapidly increasing number of affected patients. Currently, a clear relationship between COVID-19 infection incidence and/or complications due to chronic or occasional treatments for other pathologies is still not clear, albeit the COVID-19 pandemic may condition the treatment strategy of complex disorders, such as osteoarthritis (OA). Importantly, OA is the most common age-related joint disease, affecting more than 80% of people older than the age of 55, an age burden also shared with the highest severity in COVID-19 patients. OA patients often show a large array of concomitant pathologies, such as diabetes, inflammation, and cardiovascular diseases that are again shared with COVID-19 patients and may therefore increase complications. Moreover, different OA treatments, such as NSAIDs, paracetamol, corticosteroids, opioids, or other molecules have a wide array of iatrogenic effects, potentially increasing COVID-19 secondary infection incidence or complications. In this review we critically analyze the evidence on either negative or positive effects of drugs commonly used to manage OA in this particular scenario. This would provide orthopedic surgeons in particular, and physicians, pharmacologists, and clinicians in general, a comprehensive description about the safety of the current pharmacological approaches and a decision-making tool to treat their OA patients as the coronavirus pandemic continues. Twit Text FOAVip Management of Osteoarthritis During the COVID-19 Pandemic ????Clin Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=32438454 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32438454 #FOAvip English Wikipedia <ref>{{Cite pmid|32438454}}</ref> Management of Osteoarthritis During the COVID-19 Pandemic #MMPMID32438454 Ragni E; Mangiavini L; Vigano M; Brini AT; Peretti GM; Banfi G; de Girolamo L Clin Pharmacol Ther 2020[Oct]; 108 (4): 719-729 PMID32438454show ga The pandemic spread of the new coronavirus disease 2019 (COVID-19) infection in China first, and all over the world at present, has become a global health emergency due to the rapidly increasing number of affected patients. Currently, a clear relationship between COVID-19 infection incidence and/or complications due to chronic or occasional treatments for other pathologies is still not clear, albeit the COVID-19 pandemic may condition the treatment strategy of complex disorders, such as osteoarthritis (OA). Importantly, OA is the most common age-related joint disease, affecting more than 80% of people older than the age of 55, an age burden also shared with the highest severity in COVID-19 patients. OA patients often show a large array of concomitant pathologies, such as diabetes, inflammation, and cardiovascular diseases that are again shared with COVID-19 patients and may therefore increase complications. Moreover, different OA treatments, such as NSAIDs, paracetamol, corticosteroids, opioids, or other molecules have a wide array of iatrogenic effects, potentially increasing COVID-19 secondary infection incidence or complications. In this review we critically analyze the evidence on either negative or positive effects of drugs commonly used to manage OA in this particular scenario. This would provide orthopedic surgeons in particular, and physicians, pharmacologists, and clinicians in general, a comprehensive description about the safety of the current pharmacological approaches and a decision-making tool to treat their OA patients as the coronavirus pandemic continues. |*Betacoronavirus[MESH] |*Disease Management[MESH] |Analgesics, Non-Narcotic/therapeutic use[MESH] |Analgesics, Opioid/therapeutic use[MESH] |Anti-Inflammatory Agents, Non-Steroidal/therapeutic use[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/epidemiology[MESH] |Humans[MESH] |Immunosuppressive Agents/therapeutic use[MESH] |Osteoarthritis/*drug therapy/epidemiology[MESH] |Pandemics/*prevention & control[MESH] |Pneumonia, Viral/*drug therapy/epidemiology[MESH]Management of Osteoarthritis During the COVID-19 Pandemic (epmc).pdf DeepDyve Pubget Overpricing